NEWS ER
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update
NRx Pharmaceuticals (NASDAQ:NRXP) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Secured $10.8-$16.3 million in convertible-debt funding to support FDA New Drug Applications for NRX-100(ketamine) and NRX-101.
2. Plans to file NDAs for NRX-100 in suicidal depression and NRX-101 for Accelerated Approval in bipolar depression with akathisia or suicidality.
3. Reduced net loss to $7.9 million in Q2 2024, down from $8.7 million in Q2 2023.
4. Decreased R&D expenses to $2.8 million in Q2 2024 from $3.9 million in Q2 2023.
5. HOPE Therapeutics subsidiary focused on ketamine clinics planned for spinout.
1. Secured $10.8-$16.3 million in convertible-debt funding to support FDA New Drug Applications for NRX-100(ketamine) and NRX-101.
2. Plans to file NDAs for NRX-100 in suicidal depression and NRX-101 for Accelerated Approval in bipolar depression with akathisia or suicidality.
3. Reduced net loss to $7.9 million in Q2 2024, down from $8.7 million in Q2 2023.
4. Decreased R&D expenses to $2.8 million in Q2 2024 from $3.9 million in Q2 2023.
5. HOPE Therapeutics subsidiary focused on ketamine clinics planned for spinout.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1188Followers
74Following
8425Visitors
Follow